文献速递药物不良反应与药物警戒

阿柏西普玻璃体腔注射相关缺血性结肠炎首例报告

Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report.
PubMed 文献 · Br J Clin Pharmacol · 2019-02-01

报告一例80岁女性年龄相关性黄斑变性(AMD)患者,玻璃体腔注射抗VEGF药物阿柏西普后发生缺血性结肠炎。保守治疗后临床结局良好,停用阿柏西普后症状未复发。结合药物药理特性与用药后时间关联,强烈提示因果关系。

要点

  • 首例阿柏西普玻璃体腔注射后发生缺血性结肠炎的病例报告
  • 停药并保守治疗后症状缓解且未复发
  • 抗VEGF玻璃体腔注射虽全身并发症罕见,仍需警惕新发不良事件

核心结论

  • 本病例强烈提示阿柏西普玻璃体腔注射与缺血性结肠炎存在因果关系。

研究设计与样本

  • 病例报告,对象为1例80岁女性AMD患者。

主要发现

  • 患者玻璃体腔注射阿柏西普后发生缺血性结肠炎。
  • 保守治疗获得良好临床结局。
  • 停用阿柏西普后症状未再复发。

临床怎么用

  • AMD患者接受抗VEGF玻璃体腔注射时,医生应意识到仍可能出现新型不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with age-related macular degeneration (AMD), the intravitreal injection of antivascular endothelial growth factor (anti-VEGF) agents reduces disease progression and choroidal neovascularization. We report on a first case of ischaemic colitis associated with intravitreal injection of the anti-VEGF agent aflibercept in an 80-year-old female patient. Conservative treatment resulted in a favourable clinical outcome. The anti-VEGF agent was discontinued, and the symptoms did not recur. Although the intravitreal injection of anti-VEGF agents has not previously been linked to the occurrence of ischaemic colitis, consideration of aflibercept's pharmacological properties and the chronological relationship between the administration of this anti-VEGF agent and the occurrence of this systemic adverse event are strongly suggestive of a causal relationship in the present case. Although systemic complications have been rarely associated with intravitreal injections of anti-VEGF agents, physicians should be aware that novel adverse events can still occur in AMD patients treated with anti-VEGF agents.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Batteux B, Gras V, Mahboud Y, et al. Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report. Br J Clin Pharmacol. 2019. PMID: 30610744. doi:10.1111/bcp.13853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。